Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18951533 | ANALYSIS OF NUCLEIC ACID SEQUENCES | November 2024 | April 2025 | Allow | 5 | 2 | 0 | Yes | No |
| 18929514 | ANALYSIS OF NUCLEIC ACID SEQUENCES | October 2024 | February 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18810294 | PROBE-BASED ANALYSIS OF NUCLEIC ACIDS AND PROTEINS | August 2024 | June 2025 | Abandon | 10 | 1 | 0 | Yes | No |
| 18791671 | METHODS OF SEQUENCING LINKED FRAGMENTS | August 2024 | March 2025 | Allow | 8 | 1 | 1 | No | No |
| 18791664 | METHODS OF SEQUENCING LINKED FRAGMENTS | August 2024 | January 2025 | Allow | 6 | 1 | 0 | No | No |
| 18786391 | ANALYSIS OF NUCLEIC ACID SEQUENCES | July 2024 | March 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 17871420 | RECOMBINANT NUCLEIC ACID MOLECULE AND APPLICATION THEREOF IN PREPARATION OF CIRCULAR RNA | July 2022 | February 2025 | Allow | 31 | 5 | 0 | Yes | No |
| 17725042 | SINGLE-STRANDED SPLINT STRANDS AND METHODS OF USE | April 2022 | June 2024 | Allow | 26 | 4 | 0 | Yes | No |
| 17725065 | DOUBLE-STRANDED SPLINT ADAPTORS AND METHODS OF USE | April 2022 | July 2024 | Allow | 27 | 3 | 0 | Yes | No |
| 17588371 | METHOD AND INSTRUMENTATION FOR SPATIAL MULTIOMICS USING SUMI-TECHNOLOGY | January 2022 | January 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17545612 | METHOD OF GENERATING TARGETED DNA LIBRARIES | December 2021 | July 2024 | Allow | 32 | 2 | 1 | Yes | No |
| 17525553 | FUNCTIONALIZED PLASMONIC NANOSTRUCTURES | November 2021 | July 2024 | Allow | 32 | 1 | 1 | Yes | No |
| 17507697 | COMPOSITIONS AND METHODS FOR ANALYZING DNA USING PARTITIONING AND BASE CONVERSION | October 2021 | October 2024 | Allow | 36 | 2 | 0 | Yes | No |
| 17484928 | CAPTURE PROBES AND USES THEREOF | September 2021 | November 2024 | Allow | 37 | 3 | 1 | Yes | No |
| 17409731 | COMPOSITIONS AND METHODS OF LABELING MITOCHONDRIAL NUCLEIC ACIDS AND SEQUENCING AND ANALYSIS THEREOF | August 2021 | August 2024 | Allow | 36 | 1 | 0 | Yes | No |
| 17390640 | SINGLE CELL ASSAY FOR TRANSPOSASE-ACCESSIBLE CHROMATIN | July 2021 | March 2025 | Allow | 43 | 3 | 0 | No | No |
| 17376709 | TIERED LIGATION OLIGOS | July 2021 | January 2025 | Allow | 42 | 4 | 0 | No | No |
| 17182615 | METHOD FOR THE DETECTION AND QUANTIFICATION OF GENETIC ALTERATIONS | February 2021 | March 2025 | Allow | 49 | 1 | 0 | Yes | No |
| 17181947 | COMPOSITIONS AND METHODS FOR GENERATING MASSIVELY PARALLEL NUCLEIC ACID SEQUENCING LIBRARIES | February 2021 | January 2025 | Allow | 47 | 2 | 0 | No | No |
| 17166906 | BIOTIN-STREPTAVIDIN CLEAVAGE COMPOSITION AND LIBRARY FRAGMENT CLEAVAGE | February 2021 | July 2024 | Allow | 41 | 1 | 1 | No | No |
| 17161558 | BARCODED WELLS FOR SPATIAL MAPPING OF SINGLE CELLS THROUGH SEQUENCING | January 2021 | September 2024 | Allow | 44 | 2 | 1 | Yes | No |
| 17261970 | METHODS AND COMPOSITION FOR TARGETED GENOMIC ANALYSIS | January 2021 | August 2024 | Allow | 43 | 1 | 0 | No | No |
| 17254470 | SYSTEMS AND METHODS FOR INFORMATION STORAGE AND RETRIEVAL USING FLOW CELLS | December 2020 | December 2024 | Allow | 48 | 3 | 0 | Yes | No |
| 17110654 | WHOLE TRANSCRIPTOME ANALYSIS IN SINGLE CELLS | December 2020 | April 2025 | Allow | 52 | 3 | 0 | Yes | No |
| 17088594 | DEEP LEARNING ENABLED SPATIAL OPTICAL BARCODES FOR POOLED LIBRARY SCREENS | November 2020 | July 2024 | Allow | 44 | 2 | 1 | No | No |
| 17050372 | SYSTEMS AND METHODS FOR USING PATHOGEN NUCLEIC ACID LOAD TO DETERMINE WHETHER A SUBJECT HAS A CANCER CONDITION | October 2020 | October 2024 | Abandon | 48 | 0 | 1 | No | No |
| 17048533 | Identifying The Pairing Of Variable Domains Of Light And Heavy Chains Of Antibodies | October 2020 | March 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 17009386 | MEASUREMENT AND COMPARISON OF IMMUNE DIVERSITY BY HIGH-THROUGHPUT SEQUENCING | September 2020 | December 2024 | Abandon | 51 | 1 | 0 | No | No |
| 16970838 | METHODS AND COMPOSITIONS FOR ENRICHING NUCLEIC ACIDS | August 2020 | October 2024 | Allow | 50 | 2 | 1 | Yes | No |
| 16954201 | VERSATILE AMPLICON SINGLE-CELL DROPLET SEQUENCING-BASED SHOTGUN SCREENING PLATFORM TO ACCELERATE FUNCTIONAL GENOMICS | July 2020 | December 2024 | Abandon | 54 | 3 | 1 | No | No |
| 16898984 | ANALYSIS OF NUCLEIC ACID SEQUENCES | June 2020 | August 2024 | Allow | 50 | 2 | 1 | Yes | No |
| 16753241 | Multiplexed Analysis of Materials for Tissue Delivery | April 2020 | September 2024 | Allow | 53 | 1 | 1 | Yes | No |
| 16798064 | ENZYME SCREENING METHODS | February 2020 | April 2025 | Allow | 60 | 3 | 0 | No | No |
| 16625447 | TARGET-ENRICHED MULTIPLEXED PARALLEL ANALYSIS FOR ASSESSMENT OF TUMOR BIOMARKERS | December 2019 | July 2024 | Allow | 55 | 3 | 1 | No | No |
| 16542127 | TARGET ENRICHMENT BY UNIDIRECTIONAL DUAL PROBE PRIMER EXTENSION | August 2019 | November 2024 | Allow | 60 | 6 | 0 | Yes | No |
| 16435363 | REVERSING BIAS IN POLYMER SYNTHESIS ELECTRODE ARRAY | June 2019 | July 2024 | Allow | 60 | 4 | 1 | Yes | Yes |
| 16431312 | SYSTEM AND METHOD FOR IDENTIFYING THE PRESENCE OF INSECTS | June 2019 | August 2024 | Allow | 60 | 2 | 1 | Yes | No |
| 16271588 | DIAGNOSTIC, PROGNOSTIC, THERAPEUTIC AND SCREENING PROTOCOLS | February 2019 | August 2024 | Allow | 60 | 2 | 1 | Yes | No |
| 16260475 | METHODS AND COMPOSITIONS FOR DECONVOLUTING PARTITION BARCODES | January 2019 | September 2024 | Allow | 60 | 5 | 0 | Yes | No |
| 16315230 | Methods of Screening Using Barcoded Libraries | January 2019 | August 2024 | Allow | 60 | 1 | 1 | Yes | No |
| 16073622 | BOTTLENECK SEQUENCING | July 2018 | March 2025 | Allow | 60 | 7 | 0 | No | No |
| 14165453 | FLEXIBLE DISPLAY DEVICE AND DATA DISPLAYING METHOD THEREOF | January 2014 | October 2015 | Allow | 21 | 3 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PARISI, JESSICA DANIELLE.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner PARISI, JESSICA DANIELLE works in Art Unit 1684 and has examined 36 patent applications in our dataset. With an allowance rate of 91.7%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 48 months.
Examiner PARISI, JESSICA DANIELLE's allowance rate of 91.7% places them in the 76% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by PARISI, JESSICA DANIELLE receive 2.53 office actions before reaching final disposition. This places the examiner in the 86% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by PARISI, JESSICA DANIELLE is 48 months. This places the examiner in the 1% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +25.0% benefit to allowance rate for applications examined by PARISI, JESSICA DANIELLE. This interview benefit is in the 75% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 33.3% of applications are subsequently allowed. This success rate is in the 65% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 25.0% of cases where such amendments are filed. This entry rate is in the 25% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 0% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.